Author, Subjects, Keywords

Cited Author

 
 
   » By Author or Editor
 » Browse Author by Alphabet
 » By Journal
 » By Subjects
 » Malaysian Journals
 » By Type
 » By Year
 » By Latest Additions
 
 
   » By Author
 » Top 20 Authors
 » Top 20 Article
 » Top Journal Cited
 » Top Article Cited
 » Journal Citation Statistics
 » Usage Since Sept 2007


 
 
 

Login | Create Account

Innovations in Chemotherapy and Radiation Therapy: Implications and Opportunities for the Asia-Pacific Rim

Heron, D.E., and Shogan, J.E., and Mucenski, J.W., (2008) Innovations in Chemotherapy and Radiation Therapy: Implications and Opportunities for the Asia-Pacific Rim. Biomedical Imaging and Intervention Journal, 4 (3).

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
552Kb

Official URL: http://www.biij.org/2008/3/e40/e40.pdf

Affiliations

University of Pittsburgh Cancer Institute, USA, Dept. of Radiation Oncology
University of Pittsburgh Cancer Institute, USA. Dept. of Medical Oncology
University of Pittsburgh Cancer Institute, USA. Dept. of Medical Oncology

Abstract

New cases of invasive cancer in the United States occur among nearly 1.5 million people annually. In 2007, more than 1,500 people died per day with this diagnosis. Cancer is responsible for nearly one in every four deaths reported in the country. Enormous amounts of money and research have been, and are being spent, in an attempt to improve these numbers. While prevention and early detection remain the key to long-term success, treatment in the neo-adjuvant, adjuvant and metastatic settings still centre around two main treatment modalities – radiation therapy and chemotherapy. This article will review the advances that have been made in both areas that are making these treatments more precise and convenient, as well as less toxic, for the patient. In the field of radiation therapy this involves the development of new therapy planning and delivery systems, such as intensity-modulated radiation therapy (IMRT), and positron emission and computed tomography, PET-CT. Chemotherapy has also evolved with the development of targeted chemotherapy for the treatment of specific malignancies as well as improved supportive care agents which allow for the administration of dose-dense chemotherapy when appropriate.

Item Type:Journal
Keywords:Cancer, Radiation Therapy, Chemotherapy, Supportive Care
Subjects:R Medicine, Dentistry, Pharmacy, Nursing
ID Code:4622

1. American Cancer Society 2007 Stats [Online]. Available at http://www.cancer.org/docroot/STT/stt_0_2007.asp?sitearea=STT&level=1. (Accessed 18 September 2008).

2. Guillem JG, Wood WC, Moley JF et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. Ann Surg Oncol 2006; 13(10):1296-321.

3. Pisters KM, Evans WK, Azzoli CG et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007; 25(34):5506- 18.

4. Wildiers H, Kunkler I, Biganzoli L et al. Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 2007; 8(12):1101-15.

5. National Comprehensive Cancer Network [Online]. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp?button=I+Agree. (Accessed 18 September 2008).

6. Barton MB, Frommer M, Shafiq J. Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol 2006; 7(7):584-95.

7. Mackie TR. Radiation therapy treatment optimization. Introduction. Semin Radiat Oncol 1999; 9(1):1-3.

8. Purdy JA, Starkschall G, eds. A practical guide to 3-D planning and conformal radiation therapy. Madison, WI: Advanced Medical Publishing, Inc, 1999.

9. Webb S. The physics of conformal radiotherapy: Advances in technology. Bristol, UK: Institute of Physics Publishing, 1997.

10. Goitein M. Applications of computed tomography in radiotherapy treatment planning. In: Orton CG, ed. Progress in medical radiation physics. New York, NY: Plenum Press, 1982: 195-293.

11. Ling C, Rogers C, Morton R, eds. Computed tomography in radiation therapy. New York, NY: Raven Press, 1983.

12. Fraass BA, McShan DL. 3-D treatment planning. I. Overview of a clinical planning system. In: Bruinvis IAD, ed. The use of computers in radiation therapy. North-Holland, The Netherlands: Elsevier Science Publishers, 1987: 273-6.

13. Purdy JA, Wong JW, Harms WB et al. Three dimensional radiation treatment planning system. In: Bruinvis IAD et al., ed. The use of computers in radiation therapy. North-Holland, The Netherlands: Elsevier Science Publishers, 1987: 277-9.

14. Sherouse GW, Mosher Jr CE, Novis K et al. Virtual simulation: concept and implementation. In: Bruinvis IAD et al., ed. The use of computers in radiation therapy. North-Holland, The Netherlands: Elsevier Science Publishers, 1987: 433-6.

15. Mohan R, Barest G, Brewster LJ et al. A comprehensive threedimensional radiation treatment planning system. Int J Radiat Oncol Biol Phys 1988; 15(2):481-95.

16. Dearnaley DP, Khoo VS, Norman AR et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353(9149):267-72.

17. Van Houtte P. New potentials of radiotherapy in non-small cell lung cancer: stereotactic therapy and IMRT. Curr Probl Cancer 2003; 27(1):60-3.

18. Pirzkall A, Debus J, Haering P et al. Intensity modulated radiotherapy (IMRT) for recurrent, residual, or untreated skull-base meningiomas: preliminary clinical experience. Int J Radiat Oncol Biol Phys 2003; 55(2):362-72.

19. Zelefsky MJ, Fuks Z, Leibel SA. Intensity-modulated radiation therapy for prostate cancer. Semin Radiat Oncol 2002; 12(3):229-37.

20. Hurkmans CW, Cho BC, Damen E et al. Reduction of cardiac and lung complication probabilities after breast irradiation using conformal radiotherapy with or without intensity modulation. Radiother Oncol 2002; 62(2):163-71.

21. Chao KS. Protection of salivary function by intensity-modulated radiation therapy in patients with head and neck cancer. Semin Radiat Oncol 2002; 12(1 Suppl 1):20-5.

22. Ahamad A, Stevens CW, Smythe WR et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2003; 55(3):768-75.

23. Crane CH, Antolak JA, Rosen II et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer 2001; 30(3):123-32.

24. Kavanagh BD, Schefter TE, Wu Q et al. Clinical application of intensity-modulated radiotherapy for locally advanced cervical cancer. Semin Radiat Oncol 2002; 12(3):260-71.

25. Heron DE, Gerszten K, Selvaraj RN et al. Conventional 3D conformal versus intensity-modulated radiotherapy for the adjuvant treatment of gynecologic malignancies: a comparative dosimetric study of dose-volume histograms small star, filled. Gynecol Oncol 2003; 91(1):39-45.

26. Mundt AJ, Roeske JC, Lujan AE et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 2001; 82(3):456-63.

27. van de Bunt L, van der Heide UA, Ketelaars M et al. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: The impact of tumor regression. Int J Radiat Oncol Biol Phys 2006; 64(1):189-96.

28. Roeske JC, Lujan A, Rotmensch J et al. Intensity-modulated whole pelvic radiation therapy in patients with gynaecologic malignancies. Int J Radiat Oncol Biol Phys 2000; 48(5):1613-21.

29. Portelance L, Chao KS, Grigsby PW et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 2001; 51(1):261-6.

30. Ahmed RS, Kim RY, Duan J et al. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 2004; 60(2):505-12.

31. Beriwal S, Heron DE, Kim H et al. Intensity-modulated radiotherapy for the treatment of vulvar carcinoma: a comparative dosimetric study with early clinical outcome. Int J Radiat Oncol Biol Phys 2006; 64(5):1395-400.

32. Li P, Zhuang H, Mozley PD et al. Evaluation of recurrent squamous cell carcinoma of the head and neck with FDG positron emission tomography. Clin Nucl Med 2001; 26(2):131-5.

33. Nishioka T, Shiga T, Shirato H et al. Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 2002; 53(4):1051-7.

34. Balter JM, Ten Haken RK, Lawrence TS et al. Uncertainties in CT-based radiation therapy treatment planning associated with patient breathing. Int J Radiat Oncol Biol Phys 1996; 36(1):167-74.

35. Ahmad NR, Huq MS, Corn BW. Respiration-induced motion of the kidneys in whole abdominal radiotherapy: implications for treatment planning and late toxicity. Radiother Oncol 1997; 42(1):87-90.

36. Moerland MA, van den Bergh AC, Bhagwandien R et al. The influence of respiration induced motion of the kidneys on the accuracy of radiotherapy treatment planning, a magnetic resonance imaging study. Radiother Oncol 1994; 30(2):150-4.

37. Jaffray DA, Drake DG, Moreau M et al. A radiographic and tomographic imaging system integrated into a medical linear accelerator for localization of bone and soft-tissue targets. Int J Radiat Oncol Biol Phys 1999; 45(3):773-89.

38. JOHNS HE, CUNNINGHAM JR. A precision cobalt 60 unit for fixed field and rotation therapy. Am J Roentgenol Radium Ther Nucl Med 1959; 81(1):4-12.

39. Sephton R, Hagekyriakou J. A diagnostic-quality electronic portal imaging system. Radiother Oncol 1995; 35(3):240-7.

40. Stewart BW, Kleihues P, eds. World Cancer Report. WHO Press, 2003. (IARC nonserial Publication.

41. Tatsuzaki H, Levin CV. Quantitative status of resources for radiation therapy in Asia and Pacific region. Radiother Oncol 2001; 60(1):81-9.

42. IAEA Press Release: 2003/11 Millions of Cancer Victims in Developing Countries Lack Access to Life-saving Radiotherapy [Online]. Available at http://www.iaea.org/NewsCenter/ PressReleases/2003/prn200311.html. (Accessed 18 September 2008).

43. Ratain MJ, Chu E, Austin DJ et al. Pharmacology of Cancer Chemotherapy. In: Devita VT et al., eds. Cancer Principles & Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 355-521.

44. Berger AM, Kilroy TH, Kaner RJ et al. Adverse Effects of Treatment. In: Devita VT et al., eds. Cancer Principles & Practice of Oncology. 6th edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2001: 355-521.

45. [Package insert]. Genetech Inc. Herceptin. 2008.

46. Gianni L, Herman EH, Lipshultz SE et al. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008; 26(22):3777-84.

47. Telli ML, Hunt SA, Carlson RW et al. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007; 25(23):3525-33.

48. Bilancia D, Rosati G, Dinota A et al. Lapatinib in breast cancer. Ann Oncol 2007; 18 Suppl 6:vi26-30.

49. [Package insert]. GlaxoSmith Kline. Tykerb®. 2007.

50. Clinical Trials [Online]. Available at http://clinicaltrials.gov/ct2/show/NCT00098605. (Accessed September 2008).

51. Storniolo AM, Pegram MD, Overmoyer B et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008; 26(20):3317-23.

52. O’Shaughnessy J, Blackwell KL, Burstein H et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2008; 26(15S, Part I of II):abstract 1015.

53. Agus DB, Gordon MS, Taylor C et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23(11):2534-43.

54. Kharfan-Dabaja MA, Fahed R, Hussein M et al. Evolving role of monoclonal antibodies in the treatment of chronic lymphocytic leukemia. Expert Opin Investig Drugs 2007; 16(11):1799-815.

55. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008; 19(2):99-113.

56. Giusti RM, Shastri K, Pilaro AM et al. U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res 2008; 14(5):1296-302.

57. Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008; 59:237-50.

58. Nahta R, Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene 2007; 26(25):3637-43.

59. Ponz-Sarvise M, Rodriguez J, Viudez A et al. Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new? World J Gastroenterol 2007; 13(44):5877-87.

60. O'Hare T, Eide CA, Deininger MW. New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check. Expert Opin Investig Drugs 2008; 17(6):865-78.

61. Cascone T, Morelli MP, Ciardiello F. Small molecule epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in nonsmall cell lung cancer. Ann Oncol 2006; 17 Suppl 2:ii46-8.

62. Jabbour E, Cortes JE, Giles FJ et al. Current and emerging treatment options in chronic myeloid leukemia. Cancer 2007; 109(11):2171-81.

63. Wheatley-Price P, Ding K, Seymour L et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008; 26(14):2350-7.

64. Costa LJ, Drabkin HA. Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 2007; 12(12):1404-15.

65. Sterz J, von Metzler I, Hahne JC et al. The potential of proteasome inhibitors in cancer therapy. Expert Opin Investig Drugs 2008; 17(6):879-95.

66. Herrstedt J. Antiemetics: an update and the MASCC guidelines applied in clinical practice. Nat Clin Pract Oncol 2008; 5(1):32-43.

67. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24(19):3187-205.

68. Bokemeyer C, Aapro MS, Courdi A et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43(2):258-70.

69. Gnant M, Mlineritsch B, Schippinger W et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. Proc of ASCO 26(15S) Part I of II. 2008: abstract LBA4.

70. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21(21):4042-57.

71. Body JJ, Coleman R, Clezardin P et al. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007; 43(5):852-8.

72. Genomic Health Website [Online]. Available at http://www.genomichealth.com. (Accessed June 2008).

73. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351(27):2817-26.

74. National Cancer Institute Website [Online]. Available at http://www.cancer.gov/clinicaltrials/digestpage/TAILORx. (Accessed 18 September 2008).

75. Ross JS, Hatzis C, Symmans WF et al. Commercialized multigene predictors of clinical outcome for breast cancer. Oncologist 2008; 13(5):477-93.

76. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node negative breast cancer. J Natl Cancer Inst 2006; 98(17):1183-92.

77. Mook S, Schmidt MK, Viale G et al. Breast cancer patients with 1- 3 positive lymph nodes and a low risk 70-gene profile have excellent survival. Proc of 2007 SABCS. abstract 50.

78. Schwarz EM, Ritchlin CT. Clinical development of anti-RANKL therapy. Arthritis Res Ther 2007; 9 Suppl 1:S7.

79. Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68(7):901-12.

80. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008; 28(3):380-6.

81. Camacho LH. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody. Expert Opin Investig Drugs 2008; 17(3):371-85.

82. EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Online]. Available at http://clinicaltrials.gov/ct2/show/NCT00636155. (Accessed June 2008).

83. Molecule of the month. Elesclomol and obatoclax mesylate. Drug News Perspect 2008; 21(2):123-4.

84. Amgen Pipeline: AMG 655 [Online]. Available at http://www.amgen.com/investors/pipe_AMG655.html. (Accessed June 2008).

85. Donovan D, Vahdat LT. Epothilones: clinical update and future directions. Oncology (Williston Park) 2008; 22(4):408-16; discussion 416, 421, 424 passim.

86. Rugo H, Shtivelman E, Perez A et al. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat 2007; 105(1):17-28.

87. Perl AE, Carroll M. Exploiting signal transduction pathways in acute myelogenous leukemia. Curr Treat Options Oncol 2007; 8(4):265-76.

Repository Staff Only: item control page
 
 
 
 
 
 
© Copyright 2007 MyAIS Faculty of Computer Science and Information Technology, University of Malaya – All Rights Reserved. Malaysian Abstracting and Indexing System is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.